These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33782006)

  • 21. Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting.
    Adani S; Bhowmick T; Weinstein MP; Narayanan N
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of canine-specific minocycline and doxycycline susceptibility breakpoints for meticillin-resistant Staphylococcus pseudintermedius isolates from dogs.
    Hnot ML; Cole LK; Lorch G; Papich MG; Rajala-Schultz PJ; Daniels JB
    Vet Dermatol; 2015 Oct; 26(5):334-8, e70-1. PubMed ID: 26216025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae.
    Dallas SD; McGee L; Limbago B; Patel JB; McElmeel ML; Fulcher LC; Lonsway DR; Jorgensen JH
    J Clin Microbiol; 2013 Jun; 51(6):1798-802. PubMed ID: 23554197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.
    Bhat SV; Peleg AY; Lodise TP; Shutt KA; Capitano B; Potoski BA; Paterson DL
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4390-5. PubMed ID: 17938179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).
    Jean SS; Hsueh PR;
    J Glob Antimicrob Resist; 2020 Jun; 21():91-98. PubMed ID: 31627023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
    Rhodes NJ; Liu J; McLaughlin MM; Qi C; Scheetz MH
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):165-71. PubMed ID: 25801780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
    Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
    Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
    Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
    Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data.
    O'Donnell JN; Rhodes NJ; Biehle LR; Esterly JS; Patel TS; McLaughlin MM; Hirsch EB
    Int J Antimicrob Agents; 2020 Feb; 55(2):105849. PubMed ID: 31770628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
    Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
    Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.
    Avery LM; Kuti JL; Weisser M; Egli A; Rybak MJ; Zasowski EJ; Arias CA; Contreras GA; Chong PP; Aitken SL; DiPippo AJ; Wang JT; Britt NS; Nicolau DP
    Clin Infect Dis; 2019 May; 68(10):1650-1657. PubMed ID: 30188976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.
    Esterly JS; Wagner J; McLaughlin MM; Postelnick MJ; Qi C; Scheetz MH
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4885-90. PubMed ID: 22777044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.
    Defife R; Scheetz MH; Feinglass JM; Postelnick MJ; Scarsi KK
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1074-9. PubMed ID: 19075047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.